Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Silence Therapeutics plc (SLN) Ordinary 5p

Sell:550.00p Buy:553.00p 0 Change: No change
FTSE AIM 100:0.18%
Market closed Prices as at close on 19 April 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:550.00p
Buy:553.00p
Change: No change
Market closed Prices as at close on 19 April 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:550.00p
Buy:553.00p
Change: No change
Market closed Prices as at close on 19 April 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types. The Company's RNA interference (RNAi) platform is AtuRNAi. AtuRNAi is based on specific small interfering RNA (siRNA) modules, stabilization technology and other tailored features. The Company's technology is in the clinic in a Phase IIa pancreatic cancer trial. The Company has developed modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutic RNA molecules.

Contact details

Address:
72 Hammersmith Road
LONDON
W14 8TH
United Kingdom
Telephone:
+44 (020) 34576900
Website:
https://www.silence-therapeutics.com/

Important dates

Future events
There are no future events available.
Past events
Final results 30 March 2021 30/03/21
Annual report 30 March 2021 30/03/21
Interim results 14 September 2020 14/09/20
EGM 23 July 2020 23/07/20
AGM 09 June 2020 09/06/20

General stock information

EPIC:
SLN
ISIN:
GB00B9GTXM62
Market cap:
£491.69 million
Shares in issue:
89.40 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • Mark Rothera
    President, Chief Executive Officer, Director
  • Craig Tooman
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.